Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Bafisontamab by EpimAb Biotherapeutics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Bafisontamab is under clinical development by EpimAb Biotherapeutics and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to...